BioVie (NASDAQ: BIVI) director receives 211,100 stock options grant

Rhea-AI Filing Summary

BioVie Inc. director Sigmund Rogich reported new stock option awards. On January 5, 2026, he received two grants of stock options, each with a $1.31 exercise price. One grant covers 70,000 options that vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 or the company’s 2026 annual shareholders’ meeting. The second grant covers 141,100 options, of which 75% vested on January 5, 2026, and the remaining 25% vest in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029. All options are held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROGICH SIGMUND

(Last) (First) (Middle)

C/O BIOVIE INC.

680 W NYE LANE STE 201

(Street)

CARSON CITY NV 89703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.31	01/05/2026		A		70,000		(1)	01/05/2031	Common Stock	70,000	$0	70,000	D
Stock Option (right to buy)	$1.31	01/05/2026		A		141,100		(2)	01/05/2031	Common Stock	141,100	$0	141,100	D

Explanation of Responses:

1. The options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting.

2. 75% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029.

	/s/ Joanne Wendy Kim, attorney-in-fact for Sigmund Rogich	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did BioVie (BIVI) report for Sigmund Rogich?

BioVie reported that director Sigmund Rogich received two grants of stock options on January 5, 2026, covering 70,000 and 141,100 options at a $1.31 exercise price.

How many BioVie stock options did Sigmund Rogich receive in the latest Form 4?

Sigmund Rogich received 70,000 stock options in one grant and 141,100 stock options in another, each described as a Stock Option (right to buy).

What is the exercise price of the stock options granted to Sigmund Rogich at BioVie (BIVI)?

Both grants to Sigmund Rogich have an exercise price of $1.31 per share, as shown for each Stock Option (right to buy).

What is the vesting schedule for Sigmund Rogich’s 70,000 BioVie stock options?

The 70,000 options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting.

How do the 141,100 BioVie stock options granted to Sigmund Rogich vest?

For the 141,100 options, 75% vested on January 5, 2026. The remaining options vest in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.

Does Sigmund Rogich hold the reported BioVie stock options directly or indirectly?

The Form 4 indicates the options are held with ownership form marked as Direct (D), with no indirect ownership entity listed.